Cargando…
Pegylated interferon-alfa-2a monotherapy in patients infected with HCV genotype 2 and importance of rapid virological response
BACKGROUND: Pegylated (PEG)-interferon (IFN)-alfa-2a plus ribavirin (RBV) therapy for 24 weeks is now a standard treatment protocol for patients with hepatitis C virus (HCV) genotype 2. As RBV cannot be used in certain situations, we examined whether PEG-IFN-alfa-2a monotherapy for 24 weeks or less...
Autores principales: | Etoh, Reiko, Imazeki, Fumio, Kurihara, Tomoko, Fukai, Kenichi, Fujiwara, Keiichi, Arai, Makoto, Kanda, Tatsuo, Mikata, Rintaro, Yonemitsu, Yutaka, Yokosuka, Osamu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3224591/ https://www.ncbi.nlm.nih.gov/pubmed/21884572 http://dx.doi.org/10.1186/1756-0500-4-316 |
Ejemplares similares
-
Sustained Virologic Response at 24 Weeks after the End of Treatment Is a Better Predictor for Treatment Outcome in Real-World HCV-Infected Patients Treated by HCV NS3/4A Protease Inhibitors with Peginterferon plus Ribavirin
por: Kanda, Tatsuo, et al.
Publicado: (2016) -
Analysis of 5′ Nontranslated Region of Hepatitis A Viral RNA Genotype I from South Korea: Comparison with Disease Severities
por: Kanda, Tatsuo, et al.
Publicado: (2010) -
Peginterferon Alfa-2a plus Ribavirin in Japanese Patients Infected with Hepatitis C Virus Genotype 2 Who Failed Previous Interferon Therapy
por: Kanda, Tatsuo, et al.
Publicado: (2012) -
Association of IFNL3 Genotype with Hepatic Steatosis in Chronic Hepatitis C Patients Treated with Peginterferon and Ribavirin Combination Therapy
por: Nakamoto, Shingo, et al.
Publicado: (2017) -
Hepatic STAT1-Nuclear Translocation and Interleukin 28B Polymorphisms Predict Treatment Outcomes in Hepatitis C Virus Genotype 1-Infected Patients
por: Miyamura, Tatsuo, et al.
Publicado: (2011)